Catherine C Coombs MD

PubMed

• 2 citations
  Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.
  Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, Catherine Coombs, Douglas Gladstone
  Blood Advances. 2025-03-11
• Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
  Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor
  American Journal of Hematology. 2025-03-01
• Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Confere...
  Alexey V Danilov, Craig Sauter, Tycel Phillips, Catherine C Coombs, Andrew Ip
  Clinical Lymphoma, Myeloma & Leukemia. 2025-01-13

Abstracts/Posters

• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML)
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
  Catherine C. Coombs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all